About this episode
China is investing heavily in cutting-edge genetic experiments. It’s part of their quest to become a biotech superpower.
On today’s Big Take Asia Podcast, host K. Oanh Ha, Bloomberg’s Karoline Kan and Oxford University geneticist Andy Greenfield discuss China’s pharmaceutical ambitions and the loose regulatory environment that allows the animal testing industry to thrive.
Read more: China Pushes Boundaries With Animal Testing to Win Global Biotech Race
See omnystudio.com/listener for privacy information.
Get every episode summarized
Each time Big Take Asia publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Big Take Asia
Deadly Flooding in Nepal Highlights Asia’s Climate Vulnerability
Big Take Asia
How Two-Minute Microdramas Became a Billion-Dollar Industry
Big Take Asia
The Unexpected Rise of North Korea’s Economy
Big Take Asia
The Chinese AI Model Rattling Silicon Valley and Washington
Big Take Asia